[
    {
        "question": "Which types of cancer are associated with MET?",
        "answer": "Output: MET is associated with breast cancer, lung cancer, kidney cancer, pancreatic cancer, liver cancer, and gastric cancer."
    },
    {
        "question": "What drugs can treat cancers with TERT mutations?",
        "answer": "Output: TERT can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What types of cancer can be treated with diethylstilbestrol?",
        "answer": "Output: Diethylstilbestrol can treat breast cancer, ovarian cancer, and prostate cancer."
    },
    {
        "question": "Which types of cancer can be treated with pomalidomide?",
        "answer": "Output: Pomalidomide can be used to treat Kaposis sarcoma and osteosarcoma."
    },
    {
        "question": "Which genes can be activated by codeine?",
        "answer": "Output: The following genes can be activated by codeine: OPRD1, OPRK1, and OPRM1."
    },
    {
        "question": "Which genes can be activated by E7766?",
        "answer": "Output: E7766 can activate the following genes: TMEM173."
    },
    {
        "question": "What types of cancer can lonsurf be used to treat?",
        "answer": "Output: Lonsurf can be used to treat renal cell carcinoma."
    },
    {
        "question": "What types of cancer can capecitabine be used to treat?",
        "answer": "Output: Capecitabine can be used to treat breast cancer, ovarian cancer, and gastric cancer."
    },
    {
        "question": "What types of cancer can tukysa be used to treat?",
        "answer": "Output: Tukysa can be used to treat renal cell carcinoma."
    },
    {
        "question": "What types of cancer can irinotecan be used to treat?",
        "answer": "Output: Irinotecan can be used to treat colorectal cancer."
    },
    {
        "question": "What are the NMPA-approved drugs for cancers with TNKS mutations?",
        "answer": "Output: The NMPA-approved drugs for TNKS are: 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟."
    },
    {
        "question": "What are the NMPA-approved drugs for cancers with DDR2 mutations?",
        "answer": "Output: DDR2 can be treated with the following NMPA-approved drugs: 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟."
    },
    {
        "question": "What are the NMPA-approved drugs for cancers with MGMT mutations?",
        "answer": "Output: The NMPA-approved drugs for MGMT are: 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼."
    },
    {
        "question": "What are the NMPA-approved drugs for cancers with HDAC4 mutations?",
        "answer": "Output: HDAC4 can be treated with the following NMPA-approved drugs: 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟."
    },
    {
        "question": "What FDA-approved drugs are available to treat cancers with BCL2L1 mutations?",
        "answer": "Output: The FDA-approved drugs that target BCL2L1 are cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What FDA-approved drugs are available to treat cancers with GPNMB mutations?",
        "answer": "Output: GPNMB is associated with the following FDA-approved drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What FDA-approved drugs are available to treat cancers with CD3E mutations?",
        "answer": "Output: The FDA-approved drugs that have CD3E are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What genetic mutations are present in astrocytoma?",
        "answer": "Output: Astrocytoma can be caused by the following SNVs: EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What genetic mutations are present in endocervical adenocarcinoma?",
        "answer": "Output: Endocervical adenocarcinoma has the following SNVs: EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What genetic mutations are present in adenoid cystic carcinoma?",
        "answer": "Output: Adenoid cystic carcinoma can be caused by the following variants: ALK-p.L1196M, ALK-p.L1198F, ALK-p.G1202R, FLT3-p.D835Y, JAK2-p.V617F, CSF1R-p.Y546_K551del, CSF1R-p.W450_E456del, MET-skipping_mut, MET-p.L1195V, MET-p.D1228N, ERBB2-Amp, ERBB2-p.E401G, and EGFR-p.L858R."
    },
    {
        "question": "What type of cancer can be driven by PTEN-p.R173C?",
        "answer": "Output: PTEN-p.R173C can drive pancreatic cancer."
    },
    {
        "question": "What type of cancer can BRAF-p.T599K drive?",
        "answer": "Output: BRAF-p.T599K can drive melanoma."
    },
    {
        "question": "What type of cancer can VHL-p.T133N drive?",
        "answer": "Output: VHL-p.T133N can drive lung cancer."
    },
    {
        "question": "What type of cancer can be driven by ROS1-p.L2026M?",
        "answer": "Output: ROS1-p.L2026M can drive lung cancer."
    },
    {
        "question": "What type of cancer can be driven by EZH2-p.A682G?",
        "answer": "Output: EZH2-p.A682G can drive lung cancer."
    },
    {
        "question": "What FDA-approved drugs are available to treat cancers with GSK3B mutations?",
        "answer": "Output: GSK3B is associated with the following FDA-approved drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What genetic mutations are present in nipple neoplasms?",
        "answer": "Output: Nipple neoplasms can be caused by the following SNVs: ALK-p.L1196M, ALK-p.L1198F, MET-skipping_mut, MET-p.D1228N, CSF1R-p.Y546_K551del, CSF1R-p.W450_E456del, JAK2-p.V617F, FLT3-p.D835Y, ALK-p.G1202R."
    },
    {
        "question": "What types of cancer can meccnu be used to treat?",
        "answer": "Output: Meccnu can be used to treat renal cell carcinoma."
    },
    {
        "question": "What cancers are associated with the ZNFN1A3?",
        "answer": "Output: ZNFN1A3 is associated with the following cancers: renal cell carcinoma, pancreatic neuroendocrine tumor, and pancreatic cancer."
    },
    {
        "question": "Which cancers are related to the PB1?",
        "answer": "Output: PB1 is related to the following cancers: renal cell carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic exocrine tumors, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma"
    },
    {
        "question": "What is the alternative gene name for PPNAD1?",
        "answer": "Output: The alternative gene name for PPNAD1 is PPN1."
    },
    {
        "question": "What is the alternative gene name for HXB?",
        "answer": "Output: The alternative gene name for HXB is HBX1."
    },
    {
        "question": "Which cancers are related to the VRNF?",
        "answer": "Output: The following cancers are related to the VRNF: renal cell carcinoma, pancreatic neuroendocrine tumors, and pancreatic ductal adenocarcinoma."
    },
    {
        "question": "Which cancers are related to CNC?",
        "answer": "Output: CNC is related to the following cancers: renal cell carcinoma, urothelial carcinoma, and bladder carcinoma."
    },
    {
        "question": "Which drugs are FLT3 in myeloid resistant to?",
        "answer": "Output: FLT3 in myeloid are resistant to tivozanib and temsirolimus."
    },
    {
        "question": "Which drugs are EGFR in pleomorphic carcinoma of the lung resistant to?",
        "answer": "Output: Pleomorphic carcinoma of the lung are resistant to the following drugs: tivozanib, temsirolimus, and tigefur."
    },
    {
        "question": "Which drugs are colon adenocarcinoma with NTRK1 resistant to?",
        "answer": "Output: Colon adenocarcinoma with NTRK1 are resistant to the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Which drugs are KIT in soft tissue resistant to?",
        "answer": "Output: KIT in soft tissue are resistant to cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What drugs can treat cancers with ABL1 mutations?",
        "answer": "Output: ABL1 can be treated with the following NMPA-approved drugs: 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟."
    },
    {
        "question": "What genetic mutations need to be tested for erlotinib?",
        "answer": "Output: ERLOTINIB needs to be tested for the following SNVs: EGFR-p.D807V, EGFR-p.A24S, EGFR-p.C240F, EGFR-p.Q1021K, EGFR-p.A750E, EGFR-p.R681K, EGFR-p.V60A, EGFR-p.G201C, EGFR-p.T382S, EGFR-p.V1011G."
    },
    {
        "question": "How to treat gastric cancer with ERBB2?",
        "answer": "Output: Gastric cancer with ERBB2 can be treated with the following drugs: crizotinib, nivolumab, pembrolizumab, ipilimumab, and atezolizumab."
    },
    {
        "question": "What are the drug treatment options for fallopian tube carcinoma?",
        "answer": "Output: Fallopian tube carcinoma can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Which gene mutations may be resistant to sorafenib?",
        "answer": "Output: Sorafenib resistance is associated with the following genes: ALK, ROS1, EGFR, KRAS, BRAF, and MEK."
    },
    {
        "question": "How to treat bone with NTRK1?",
        "answer": "Output: NTRK1 can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Which genetic mutations need to be detected by FIIN-1?",
        "answer": "Output: FIIN-1 can detect the following SNVs: ALK, EGFR, BRAF, MEK, PIK3CA, PTEN, and PIK3CB."
    },
    {
        "question": "What are the drug treatment options for bladder urothelial carcinoma?",
        "answer": "Output: Bladder urothelial carcinoma can be treated with the following drugs: vinflunine, nadofaragene firadenovec-vncg, and chemotherapy."
    },
    {
        "question": "Which genetic mutations are possibly related to sensitivity to afatinib?",
        "answer": "Output: The following SNVs are possibly related to sensitivity to afatinib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "Which genetic mutations need to be detected for MK-2206?",
        "answer": "Output: MK-2206 needs to detect the following SNVs:"
    },
    {
        "question": "What are the genetic mutations in pancreas?",
        "answer": "Output: The snvfull in pancreas are: ALK-p.L1196M, ALK-p.L1198F, MET-skipping_mut, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, ALK-p.G1202R, JAK2-p.V617F, FLT3-p.D835Y."
    },
    {
        "question": "What drugs can treat cancers with MTOR mutations?",
        "answer": "Output: MTOR can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the genetic mutations in esophageal carcinoma?",
        "answer": "Output: The snvfull in esophageal carcinoma are ALK-p.L1196M, ALK-p.L1198F, MET-skipping_mut, MET-p.D1228N, CSF1R-p.Y546_K551del, CSF1R-p.W450_E456del, JAK2-p.V617F, FLT3-p.D835Y, ALK-p.G1202R."
    },
    {
        "question": "What types of cancer can sotorasib treat?",
        "answer": "Output: Sotorasib can treat non-small cell lung cancer."
    },
    {
        "question": "What types of cancer can aldesleukin treat?",
        "answer": "Output: Aldesleukin can treat leukemia."
    },
    {
        "question": "What types of cancer can be treated with abarelix?",
        "answer": "Output: Abarelix can treat renal cell carcinoma."
    },
    {
        "question": "What types of cancer can be treated with bexarotene?",
        "answer": "Output: Bexarotene can be used to treat T cell leukemia/lymphoma."
    },
    {
        "question": "What types of cancer can be treated with bortezomib?",
        "answer": "Output: Bortezomib can be used to treat multiple myeloma, chronic lymphocytic leukemia, and other types of cancer."
    },
    {
        "question": "Which drugs are ALK in giant cell carcinoma of the lung resistant to?",
        "answer": "Output: ALK in giant cell carcinoma of the lung are resistant to clotozantinib and luminaspib."
    },
    {
        "question": "What drugs can treat cancers with ALK mutations?",
        "answer": "Output: ALK can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the genetic mutations in liver?",
        "answer": "Output: Liver can be caused by the following snvfull: EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "Which genetic mutations need to be detected for thyroid?",
        "answer": "Output: The following snvfull need to be detected for thyroid: EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What are the genetic mutations in cervix?",
        "answer": "Output: The snvfull in cervix are: ALK-p.L1196M, ALK-p.L1198F, JAK2-p.V617F, FLT3-p.D835Y, ALK-p.G1202R."
    },
    {
        "question": "What disease does a mutation in the MYH8 gene cause?",
        "answer": "Output: A mutation in the MYH8 gene causes three-headed dactyly-camptodactyly syndrome."
    },
    {
        "question": "What disease does a PDGFRA gene mutation cause?",
        "answer": "Output: A PDGFRA gene mutation can cause a rare genetic disorder called familial gastrointestinal stromal tumors."
    },
    {
        "question": "What disease does a mutation in the CYLD gene cause?",
        "answer": "Output: A mutation in the CYLD gene causes familial cylindromatosis."
    },
    {
        "question": "What diseases are caused by cancers with AIRE mutations?",
        "answer": "Output: AIRE is a rare genetic disorder that causes a variety of diseases, including autoimmune polyendocrinopathy-dandidaosis-ectodermal dystrophy, autoimmune polyendocrinopathy-dandidaosis-ectodermal dystrophy-renal cell carcinoma, and autoimmune polyendocrinopathy-dandidaosis-ectodermal dystrophy-pancreatic neuroendocrine tumor."
    },
    {
        "question": "What disease does a mutation in the XIAP gene cause?",
        "answer": "Output: A mutation in the XIAP gene causes X-linked inherited amyloidosis."
    },
    {
        "question": "What disease does a PALB2 gene mutation cause?",
        "answer": "Output: A mutation in the XIAP gene causes X-linked inherited amyloidosis."
    },
    {
        "question": "What are the fusion genes in skin?",
        "answer": "Output: The fusion in skin is ALK-p.L1196M, ALK-p.L1198F, ALK-p.G1202R, ALK-p.C1156Y, FGFR2-SKI, FGFR3-TACC3, FGFR2-TACC3, FGFR2-CLIP1, and FGFR2-SHTN1."
    },
    {
        "question": "What are the fusion in pelvic tumor?",
        "answer": "Output: The fusion in pelvic tumor is ALK-p.L1196M, ALK-p.L1198F, ALK-p.G1202R, ALK-p.C1156Y, FGFR2-SKI, FGFR3-TACC3, FGFR2-TACC3, FGFR2-CLIP1, and FGFR2-SHTN1."
    },
    {
        "question": "What are the fusion genes in lymphoepithelioma-like carcinoma of the lung?",
        "answer": "Output: Lymphoepithelioma-like carcinoma of the lung has the following fusion genes: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK, and ALK-p.F1245C."
    },
    {
        "question": "What are the fusion genes in pancreatic neuroendocrine tumor?",
        "answer": "Output: Pancreatic neuroendocrine tumor can be caused by the following fusion genes: ALK-FGFR2, ALK-FGFR3, ALK-SKI, ALK-TACC3, ALK-CLIP1, ALK-SHTN1, FGFR2-SKI, FGFR2-TACC3, FGFR2-CLIP1, FGFR2-SHTN1, FGFR3-TACC3, FGFR3-CLIP1, FGFR3-SHTN1."
    },
    {
        "question": "What are the fusion genes in melanoma?",
        "answer": "Output: The fusion genes in melanoma are ALK-p.L1196M, ALK-p.L1198F, ALK-p.G1202R, ALK-p.C1156Y, FGFR2-SKI, FGFR3-TACC3, FGFR2-TACC3, FGFR2-CLIP1, and FGFR2-SHTN1."
    },
    {
        "question": "What are the fusion genes in inflammatory myofibroblastic tumor?",
        "answer": "Output: Inflammatory myofibroblastic tumor can be caused by the following fusion: ALK-p.L1196M, ALK-p.L1198F, ALK-p.G1202R, ALK-p.C1156Y, FGFR2-SKI, FGFR3-TACC3, FGFR2-TACC3, FGFR2-CLIP1, FGFR2-SHTN1, and FGFR1."
    },
    {
        "question": "What are the fusion genes in soft tissue?",
        "answer": "Output: The fusion genes in soft tissue are ALK, FGFR2-SKI, FGFR3-TACC3, FGFR2-TACC3, FGFR2-CLIP1, and FGFR2-SHTN1."
    },
    {
        "question": "What type of cancer can be induced by Trismus-Pseudocamptodactyly Syndrome with Cardiac Myxoma and Freckling?",
        "answer": "Output: Trismus-Pseudocamptodactyly Syndrome with Cardiac Myxoma and Freckling can induce cardiac myxoma."
    },
    {
        "question": "Which drugs are KRAS in colon cancer sensitive to?",
        "answer": "Output: KRAS in colon cancer are sensitive to tigefur."
    },
    {
        "question": "What genetic mutations need to be tested before lung?",
        "answer": "Output: The following variants need to be tested before lung: EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What is the gender of the clinical trial recruiting prostate patients?",
        "answer": "Output: The gender of the clinical trial recruiting prostate patients is male."
    },
    {
        "question": "Which drugs are ALK in basaloid large cell carcinoma of the lung sensitivity to?",
        "answer": "Output: ALK in basaloid large cell carcinoma of the lung are sensitive to cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Are there any suitable and currently recruiting clinical trials for patients with esophageal adenocarcinoma in China?",
        "answer": "Output: There are clinical trials for patients with esophageal adenocarcinoma in China."
    },
    {
        "question": "What drugs are available for cancers with ERBB2 mutations?",
        "answer": "Output: The following drugs are available for ERBB2 mutations: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Are there suitable and currently recruiting clinical trials for non-small cell lung cancer patients?",
        "answer": "NA"
    },
    {
        "question": "Are there suitable and currently recruiting clinical trials for liver patients?",
        "answer": "Output: There are clinical trials for liver patients: Clinical trial 1, Clinical trial 2, Clinical trial 3, Clinical trial 4, Clinical trial 5, Clinical trial 6, Clinical trial 7, Clinical trial 8, Clinical trial 9, Clinical trial 10, Clinical trial 11, Clinical trial 12, Clinical trial 13, Clinical trial 14, Clinical trial 15, Clinical trial 16, Clinical trial 17, Clinical trial 18, Clinical trial 19, Clinical trial 20, Clinical trial 21, Clinical trial 22, Clinical trial 23, Clinical trial 24, Clinical trial 25, Clinical trial 26, Clinical trial 27, Clinical trial 28, Clinical trial 29, Clinical trial 30, Clinical trial 31, Clinical trial 32, Clinical trial 33, Clinical trial 34, Clinical trial 35, Clinical trial 36, Clinical trial 37, Clinical trial 38, Clinical trial 39, Clinical trial 40, Clinical trial 41, Clinical trial 42, Clinical trial 43, Clinical trial 44, Clinical trial 45, Clinical trial 46, Clinical trial 47, Clinical trial 48, Clinical trial 49, Clinical trial 50, Clinical trial 51, Clinical trial 52, Clinical trial 53, Clinical trial 54, Clinical trial 55, Clinical trial 56, Clinical trial 57, Clinical trial 58, Clinical trial 59, Clinical trial 60, Clinical trial 61, Clinical trial 62, Clinical trial 63, Clinical trial 64, Clinical trial 65, Clinical trial 66, Clinical trial 67, Clinical trial 68, Clinical trial 69, Clinical trial 70, Clinical trial 71, Clinical trial 72, Clinical trial 73, Clinical trial 74, Clinical trial 75, Clinical trial 76, Clinical trial 77, Clinical trial 78, Clinical trial 79, Clinical trial 80, Clinical trial 81, Clinical trial 82, Clinical trial 83, Clinical trial 84, Clinical trial 85, Clinical trial 86, Clinical trial 87, Clinical trial 88, Clinical trial 89, Clinical trial 90, Clinical trial 91, Clinical trial 92, Clinical trial 93, Clinical trial 94, Clinical trial 95, Clinical trial 96, Clinical trial 97, Clinical trial 98, Clinical trial 99, Clinical trial 100, Clinical trial 101, Clinical trial 102, Clinical trial 103, Clinical trial 104, Clinical trial 105, Clinical trial 106, Clinical trial 107, Clinical trial 108, Clinical trial 109, Clinical trial 110, Clinical trial 111, Clinical trial 112, Clinical trial 113, Clinical trial 114, Clinical trial 115, Clinical trial 116, Clinical trial 117, Clinical trial 118, Clinical trial 119, Clinical trial 120, Clinical trial 121, Clinical trial 122, Clinical trial 123, Clinical trial 124, Clinical trial 125, Clinical trial 126, Clinical trial 127, Clinical trial 128, Clinical trial 129, Clinical trial 130, Clinical trial 131, Clinical trial 132, Clinical trial 133, Clinical trial 134, Clinical trial 135, Clinical trial 136, Clinical trial 137, Clinical trial 138, Clinical trial 139, Clinical trial 140, Clinical trial 141, Clinical trial 142, Clinical trial 143, Clinical trial 144, Clinical trial 145, Clinical trial 146, Clinical trial 147, Clinical trial 148, Clinical trial 149, Clinical trial 150, Clinical trial 151, Clinical trial 152, Clinical trial 153, Clinical trial 154, Clinical trial 155, Clinical trial 156, Clinical trial 157, Clinical trial 158, Clinical trial 159, Clinical trial 160, Clinical trial 161, Clinical trial 162, Clinical trial 163, Clinical trial 164, Clinical trial 165, Clinical trial 166, Clinical trial 167, Clinical trial 168, Clinical trial 169, Clinical trial 170, Clinical trial 171, Clinical trial 172, Clinical trial 173, Clinical trial 174, Clinical trial 175, Clinical trial 176, Clinical trial 177, Clinical trial 178, Clinical trial 179, Clinical trial 180, Clinical trial 181, Clinical trial 182, Clinical trial 183, Clinical trial 184, Clinical trial 185, Clinical trial 186, Clinical trial 187, Clinical trial 188, Clinical trial 189, Clinical trial 190, Clinical trial 191, Clinical trial 192, Clinical trial 193, Clinical trial 194, Clinical trial 195, Clinical trial 196, Clinical trial 197, Clinical trial 198,"
    },
    {
        "question": "Are there suitable and currently recruiting clinical trials for lung patients in China?",
        "answer": "Output: Yes, there are clinical trials suitable for lung patients in China."
    },
    {
        "question": "What are the genetic mutations in ovarian carcinoma?",
        "answer": "Output: Ovarian carcinoma can be caused by the following SNVs: ALK-p.L1196M, ALK-p.L1198F, MET-skipping_mut, MET-p.D1228N, CSF1R-p.Y546_K551del, CSF1R-p.W450_E456del, JAK2-p.V617F, FLT3-p.D835Y, ALK-p.G1202R."
    },
    {
        "question": "What are the genetic mutations in kidney?",
        "answer": "Output: The snvfull in kidney are EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What are the mutations in endometrial carcinoma?",
        "answer": "Output: Endometrial carcinoma can be caused by the following mutations: EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-skipping_mut, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What are the genetic mutations in small cell lung cancer?",
        "answer": "Output: Small cell lung cancer can be caused by the following variants: ALK-p.L1196M, ALK-p.L1198F, MET-skipping_mut, MET-p.D1228N, CSF1R-p.Y546_K551del, CSF1R-p.W450_E456del, JAK2-p.V617F, FLT3-p.D835Y, ALK-p.G1202R."
    },
    {
        "question": "What are the genetic mutations in liver?",
        "answer": "Output: The snvfull in liver are EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What are the genetic mutations in breast?",
        "answer": "Output: The snvfull in breast are EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "What is the minimum age for recruitment in clinical trials for small bowel cancer patients?",
        "answer": "Output: The minimum age for recruitment in clinical trials for small bowel cancer patients is 18 years old."
    },
    {
        "question": "What is the minimum age for recruitment of clinical trials for cancer of unknown primary?",
        "answer": "Output: The minimum age for recruitment of clinical trials for cancer of unknown primary is 18 years old."
    },
    {
        "question": "What is the minimum age for recruitment of patients with ependymoma in clinical trials?",
        "answer": "Output: The minimum age for recruitment of patients with ependymoma in clinical trials is 18 years old."
    },
    {
        "question": "What is the maximum age for recruitment of clinical trials for patients with meningioma?",
        "answer": "Output: The maximum age for recruitment of clinical trials for patients with meningioma is 80 years old."
    },
    {
        "question": "What are the drug treatment options for esophageal squamous cell carcinoma?",
        "answer": "Output: Esophageal squamous cell carcinoma can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Which genetic mutations are possibly related to sensitivity to debio 1347?",
        "answer": "Output: The following SNVs are possibly related to sensitivity to debio 1347: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What is the maximum age for recruitment of oral carcinoma patients in clinical trials?",
        "answer": "Output: The maximum age for recruitment of oral carcinoma patients in clinical trials is 80 years old."
    },
    {
        "question": "What is the gender of the clinical trial recruiting patients with renal medullary carcinoma?",
        "answer": "Output: The gender of the clinical trial recruiting patients with renal medullary carcinoma is not specified."
    },
    {
        "question": "What is the gender of the clinical trial recruiting patients with lung adenosquamous carcinoma?",
        "answer": "Output: The gender of the clinical trial recruiting patients with lung adenosquamous carcinoma is not specified."
    },
    {
        "question": "What is the gender of the clinical trial participants recruited for pancreas?",
        "answer": "Output: The gender of the clinical trial participants recruited for pancreas is male."
    },
    {
        "question": "What is the gender of the clinical trial recruiting patients with penis?",
        "answer": "Output: The gender of the clinical trial recruiting patients with penis is not specified."
    },
    {
        "question": "What is the gender of the clinical trial recruiting peritoneum patients?",
        "answer": "Output: The gender of the clinical trial recruiting peritoneum patients is not specified."
    },
    {
        "question": "What FDA-approved drugs target cancers with ERBB2 mutations?",
        "answer": "Output: The FDA-approved drugs that target ERBB2 mutations are: cabozantinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What FDA-approved drugs target cancers with PSMC5 mutations?",
        "answer": "Output: The FDA-approved drugs that target PSMC5 mutations are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the NMPA-approved drugs for cancers with AR mutation?",
        "answer": "Output: NMPA-approved drugs for AR mutation are arsenic trioxide and arsenic sulfate."
    },
    {
        "question": "What are the targeted drugs for cancers with PIK3CA mutation?",
        "answer": "Output: The targeted drugs for PIK3CA mutation are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the targeted drugs for cancers with TP53 mutation?",
        "answer": "Output: The targeted drugs for TP53 mutation are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the NMPA-approved drugs for cancers with IDH1 mutation?",
        "answer": "Output: The NMPA-approved drugs for IDH1 mutation are: 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加氟, 替加�"
    },
    {
        "question": "What NMPA-approved drugs are available for cancers with EGFR mutations?",
        "answer": "Output: EGFR mutations can be treated with the following NMPA-approved drugs: gefitinib, erlotinib, afatinib, osimertinib, and crizotinib."
    },
    {
        "question": "What genetic diseases can cancers with PALB2 mutations cause?",
        "answer": "Output: PALB2 mutations can cause breast cancer, familial adenomatous polyposis, and familial breast cancer."
    },
    {
        "question": "What genetic diseases can be caused by cancers with AR mutations?",
        "answer": "Output: AR mutations can cause the following genetic diseases: Ewing's sarcoma, Li-Fraumeni syndrome, and primary hyperparathyroidism."
    },
    {
        "question": "What type of genetic disease can be caused by cancers with PPM1D mutation?",
        "answer": "Output: PPM1D mutation can cause breast cancer and ovarian cancer."
    },
    {
        "question": "What genetic diseases may be caused by cancers with SLC37A4?",
        "answer": "Output: SLC37A4 may cause the following genetic diseases: ⅠB型糖原贮积病, ⅡB型糖原贮积病, ⅢB型糖原贮积病, ⅣB型糖原贮积病, ⅤB型糖原贮积病, ⅥB型糖原贮积病, ⅦB型糖原贮积病, ⅧB型糖原贮积病, ⅨB型糖原贮积病, ⅩB型糖原贮积病, ⅪB型糖原贮积病, ⅫB型糖原贮积病, ⅬB型糖原贮积病, ⅭB型糖原贮积病, ⅮB型糖原贮积病, ⅯB型糖原贮积病, ⅰB型糖原贮积病, ⅱB型糖原贮积病, ⅲB型糖原贮积病, ⅳB型糖原贮积病, ⅴB型糖原贮积病, ⅵB型糖原贮积病, ⅶB型糖原贮积病, ⅷB型糖原贮积病, ⅸB型糖原贮积病, ⅹB型糖原贮积病, ⅺB型糖原贮积病, ⅻB型糖原贮积病, ⅼB型糖原贮积病, ⅽB型糖原贮积病, ⅾB型糖原贮积病, ⅿB型糖原贮积病, ↀB型糖原贮积病, ↁB型糖原贮积病, ↂB型糖原贮积病, ↃB型糖原贮积病, ↄB型糖原贮积病, ↅB型糖原贮积病, ↆB型糖原贮积病, ↇB型糖原贮积病, ↈB型糖原贮积病, ↉B型糖原贮积病, ↊B型糖原贮积病, ↋B型糖原贮积病, ↌B型糖原贮积病, ↍B型糖原贮积病, ↎B型糖原贮积病, ↏B型糖原贮积病, ←B型糖原贮积病, ↑B型糖原贮积病, →B型糖原贮积病, ↓B型糖原贮积病, ↔B型糖原贮积病, ↕B型糖原贮积病, ↖B型糖原贮积病, ↗B型糖原贮积病, ↘B型糖原贮积病, ↙B型糖原贮积病, ↚B型糖原贮积病, ↛B型糖原贮积病, ↜B型糖原贮积病, ↝B型糖原贮积病, ↞B型糖原贮积病, ↟B型糖原贮积病, ↠B型糖原贮积病, ↡B型糖原贮积病, ↢B型糖原贮积病, ↣B型糖原贮积病, ↤B型糖原贮积病, ↥B型糖原贮积病, ↦B型糖原贮积病, ↧B型糖原贮积病, ↨B型糖原贮积病, ↩B型糖原贮积病, ↪B型糖原贮积病, ↫B型糖原贮积病, ↬B型糖原贮积病, ↭B型糖原贮积病, ↮B型糖原贮积病, ↯B型糖原贮积病, ↰B型糖原贮积病, ↱B型糖原贮积病, ↲B型糖原贮"
    },
    {
        "question": "What genetic diseases can be caused by cancers with PKD1 mutations?",
        "answer": "Output: PKD1 mutations can cause polycystic kidney disease 1."
    },
    {
        "question": "Is there a strong association between BRCA1 gene mutation and ovarian carcinoma?",
        "answer": "Output: Yes, there is a strong association between BRCA1 gene mutation and ovarian carcinoma."
    },
    {
        "question": "What is the relationship between Galactosemia and liver?",
        "answer": "Output: Galactosemia is a disease that develops from the lack of the enzyme galactose-1-phosphate uridyltransferase, which is responsible for the metabolism of galactose. It is a rare disease that can cause liver damage and other complications."
    },
    {
        "question": "What type of cancer can be driven by MET-p.D1230N?",
        "answer": "Output: MET-p.D1230N can drive skin melanoma."
    },
    {
        "question": "What types of cancer can BRAF-p.D594N potentially cause?",
        "answer": "Output: BRAF-p.D594N can potentially cause skin melanoma."
    },
    {
        "question": "What types of cancer can PDGFRA-p.N659K potentially lead to?",
        "answer": "Output: PDGFRA-p.N659K can potentially lead to skin melanoma."
    },
    {
        "question": "What type of cancer can be driven by EGFR-p.V834L?",
        "answer": "Output: EGFR-p.V834L can drive renal cell carcinoma."
    },
    {
        "question": "Which types of cancer can BRAF-p.G606E induce?",
        "answer": "Output: BRAF-p.G606E can induce melanoma."
    },
    {
        "question": "What type of cancer can KIT-p.D816V drive?",
        "answer": "Output: KIT-p.D816V can drive renal cell carcinoma."
    },
    {
        "question": "With which forms of cancer is MAP2K1-p.C121S associated?",
        "answer": "Output: MAP2K1-p.C121S is associated with skin melanoma."
    },
    {
        "question": "What type of clinical trial is NCT03280160?",
        "answer": "Output: NCT03280160 is a multicenter, non-randomized, open label study."
    },
    {
        "question": "What is the clinical trial NCT04549064 about?",
        "answer": "Output: NCT04549064 is a clinical trial about the identification of AREG for the detection of pancreatic cancer by biosensor."
    },
    {
        "question": "What is the clinical trial NCT01921751 about?",
        "answer": "Output: NCT01921751 is a phase II randomized trial evaluating the addition of high or standard intensity radiation to gemcitabine and nab-paclitaxel for locally advanced pancreatic cancer."
    },
    {
        "question": "What is the clinical trial NCT00514969 about?",
        "answer": "Output: NCT00514969 is a phase II study of STI571 for the treatment of patients with Ph+ chronic myeloid leukemia in accelerated and blastic phase."
    },
    {
        "question": "What type of clinical trial is NCT04015622?",
        "answer": "Output: NCT04015622 is a randomized phase II trial."
    },
    {
        "question": "What diseases can a mutation in the DHH gene cause?",
        "answer": "Output: A mutation in the DHH gene can cause Swyer syndrome."
    },
    {
        "question": "What diseases are associated with the cancers with ERCC2 gene mutations?",
        "answer": "Output: The ERCC2 gene is associated with the following diseases: xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma pigmentosum, xeroderma p"
    },
    {
        "question": "Which drugs are ERBB2-p.D769Y resistance to?",
        "answer": "Output: The following drugs show resistance to ERBB2-p.D769Y: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Which drugs are EGFR-p.G719A mutation sensitive to?",
        "answer": "Output: The drugs sensitive to EGFR-p.G719A mutation are gefitinib, erlotinib, afatinib, and osimertinib."
    },
    {
        "question": "Which drug does cancers with ALK-p.I1171T show resistance to?",
        "answer": "Output: ALK-p.I1171T shows resistance to cabozantinib."
    },
    {
        "question": "Which drugs are cancers with NTRK3-p.G623R resistant to?",
        "answer": "Output: NTRK3-p.G623R is resistant to cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Which drugs does cancers with BRAF-p.G466V show resistance to?",
        "answer": "Output: BRAF-p.G466V shows resistance to the following drugs: 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, 替加氟, 伏罗尼布, 替加氟, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单"
    },
    {
        "question": "Which cancers are associated with cancers with FLT3 mutations?",
        "answer": "Output: FLT3 mutations are associated with the following cancers: non-small cell lung cancer, gastric cancer, small cell lung cancer, and renal cell carcinoma."
    },
    {
        "question": "Which types of cancer are related to cancers with EGFR mutations?",
        "answer": "Output: EGFR mutations are related to the following types of cancer: non-small cell lung cancer, gastric cancer, stomach cancer, small cell lung cancer, and pancreatic cancer."
    },
    {
        "question": "What types of cancer can be treated with avelumab?",
        "answer": "Output: Avelumab can be used to treat Merkel cell carcinoma, renal cell carcinoma, and urothelial carcinoma."
    },
    {
        "question": "What types of cancer can be treated with proleukin?",
        "answer": "Output: Proleukin can treat leukemia."
    },
    {
        "question": "What are the fusion genes in alveolar rhabdomyosarcoma?",
        "answer": "Output: Alveolar rhabdomyosarcoma can be caused by the following fusion genes: ALK-p.L1196M, ALK-p.L1198F, ALK-p.G1202R, ALK-p.C1156Y, FGFR2-SKI, FGFR3-TACC3, FGFR2-TACC3, FGFR2-CLIP1, and FGFR2-SHTN1."
    },
    {
        "question": "What is the relationship between FGFR3 and the ponatinib?",
        "answer": "Output: FGFR3 is positively regulated by SRC and inhibited by ponatinib."
    },
    {
        "question": "What types of cancer can ponatinib be used to treat?",
        "answer": "Output: Ponatinib can be used to treat acute lymphoblastic leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia."
    },
    {
        "question": "What are the drug treatment options for bladder urothelial carcinoma?",
        "answer": "Output: Bladder urothelial carcinoma can be treated with the following drugs: vinflunine, nadofaragene firadenovec-vncg, and chemotherapy."
    },
    {
        "question": "What are the drug treatment options for non-squamous non-small cell lung cancer?",
        "answer": "Output: Non-squamous non-small cell lung cancer can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the drug treatment options for thyroid?",
        "answer": "Output: Thyroid can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What is the relationship between NRAS and the RO5126766?",
        "answer": "Output: The relationship between NRAS and RO5126766 is: NRAS regulates the activation of BRAF, and BRAF inhibits RO5126766."
    },
    {
        "question": "What is the relationship between ALK and the crizotinib?",
        "answer": "Output: ALK is inhibited by crizotinib."
    },
    {
        "question": "What are the fusion genes in t-lymphoblastic leukemia/lymphoma?",
        "answer": "Output: The fusion genes in t-lymphoblastic leukemia/lymphoma are: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK, and ALK-p.F1245C."
    },
    {
        "question": "What is the relationship between RET and the selpercatinib?",
        "answer": "Output: RET is inhibited by selpercatinib."
    },
    {
        "question": "Which genetic mutations are possibly related to sensitivity to alectinib?",
        "answer": "Output: The following snvfull are possibly related to sensitivity to alectinib: ALK-p.H1002R, ALK-p.G1402C, ALK-p.E766K, ALK-p.S413T, ALK-p.E1568D, ALK-p.A537G, ALK-p.N661I, ALK-p.Q453H, ALK-p.I725F, ALK-p.S237Y."
    },
    {
        "question": "What are the drug treatment options for ovarian carcinoma?",
        "answer": "Output: Ovarian carcinoma can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "Which genetic mutations are possibly related to sensitivity to sorafenib?",
        "answer": "Output: The following SNVs are possibly related to sensitivity to sorafenib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What types of cancer can be treated with everolimus?",
        "answer": "Output: Everolimus can be used to treat the following types of cancer: pancreatic cancer, renal cell carcinoma, and breast cancer."
    },
    {
        "question": "What is the relationship between ERBB2 and the A166?",
        "answer": "Output: The A166 is a mutation of the ERBB2 gene."
    },
    {
        "question": "Which genetic mutations are possibly related to sensitivity to pazopanib?",
        "answer": "Output: The following snvfulls are possibly related to sensitivity to pazopanib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What is the relationship between PDGFRA and the dasatinib?",
        "answer": "Output: Dasatinib is an inhibitor of PDGFRA."
    },
    {
        "question": "How does EGFR gene mutation affect the efficacy of gefitinib?",
        "answer": "Output: Gefitinib is effective against EGFR gene mutation."
    },
    {
        "question": "What types of cancer can lorlatinib be used to treat?",
        "answer": "Output: Lorlatinib can be used to treat renal cell carcinoma (RCC) and other types of cancer that have ALK mutations."
    },
    {
        "question": "What is the relationship between MET and the cabozantinib?",
        "answer": "Output: MET is inhibited by cabozantinib."
    },
    {
        "question": "What types of cancer can be treated with bevacizumab?",
        "answer": "Output: Bevacizumab can be used to treat the following types of cancer: uterine corpus endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, gastric cancer, stomach cancer, small intestine cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, kidney cancer, bladder cancer, uterine cancer, cervical cancer, endometrial cancer, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma, small intestine sarcoma, colon sarcoma, rectal sarcoma, liver sarcoma, pancreatic sarcoma, kidney sarcoma, bladder sarcoma, uterine carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcoma, ovarian sarcoma, fallopian tube sarcoma, primary peritoneal sarcoma, gastric sarcoma, stomach sarcoma"
    },
    {
        "question": "How to treat cervix with PIK3CA activating mutation?",
        "answer": "Output: Cervix with PIK3CA activating mutation can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What genetic mutations need to be tested for gefitinib?",
        "answer": "Output: Gefitinib needs to be tested for the following SNVs: EGFR-p.D807V, EGFR-p.A24S, EGFR-p.C240F, EGFR-p.Q1021K, EGFR-p.A750E, EGFR-p.R681K, EGFR-p.V60A, EGFR-p.G201C, EGFR-p.T382S, EGFR-p.V1011G."
    },
    {
        "question": "Which genetic mutations need to be tested for brigatinib?",
        "answer": "Output: Brigatinib needs to be tested for the following snvfulls: ALK-p.H1002R, ALK-p.G1402C, ALK-p.E766K, ALK-p.S413T, ALK-p.E1568D, ALK-p.A537G, ALK-p.N661I, ALK-p.Q453H, ALK-p.I725F, ALK-p.S237Y."
    },
    {
        "question": "Which genetic mutations are possibly related to sensitivity to dacomitinib?",
        "answer": "Output: The following SNVs are possibly related to sensitivity to dacomitinib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What types of cancer can be treated by dtie?",
        "answer": "Output: DTIE can treat renal cell carcinoma."
    },
    {
        "question": "What types of cancer can be treated with act-d?",
        "answer": "Output: Act-d can treat renal cell carcinoma."
    },
    {
        "question": "What types of cancer can carmustine (product) treat?",
        "answer": "Output: Carmustine (product) can treat the following types of cancer: renal cell carcinoma, lymphoma, leukemia, and non-Hodgkin lymphoma."
    },
    {
        "question": "Which types of cancer can be treated with bleomicin?",
        "answer": "Output: Bleomicin can be used to treat the following types of cancer: renal cell carcinoma, bladder cancer, and urothelial carcinoma."
    },
    {
        "question": "Which types of cancer can be driven by cancers with E3B1 mutations?",
        "answer": "Output: E3B1 can drive the following types of cancer: renal cell carcinoma, pancreatic neuroendocrine tumors, and pancreatic ductal adenocarcinoma."
    },
    {
        "question": "Which cancers are related to the ABLBP4?",
        "answer": "Output: ABLBP4 is related to the following cancers: skin melanoma."
    },
    {
        "question": "What are the genetic mutations in lung adenocarcinoma?",
        "answer": "Output: The snvfull in lung adenocarcinoma are EGFR-p.L861R, EGFR-p.G719A, ERBB2-p.E401G, ALK-p.L1196M, MET-p.L1195V, CSF1R-p.Y546_K551del, MET-p.D1228N, CSF1R-p.W450_E456del, JAK2-p.V617F, ALK-p.L1198F."
    },
    {
        "question": "Which drugs are related to the efficacy of BRAF?",
        "answer": "Output: The drugs related to the efficacy of BRAF are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the drug treatment options for renal cell carcinoma?",
        "answer": "Output: Renal cell carcinoma can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What are the drug treatment options for lymphoid?",
        "answer": "Output: Lymphoid can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What is the relationship between KRAS and the RG6330?",
        "answer": "Output: KRAS is the inhibition_to of RG6330."
    },
    {
        "question": "Which genetic mutations are potentially associated with sensitivity to osimertinib?",
        "answer": "Output: The following SNVs are potentially associated with sensitivity to osimertinib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What are the drug treatment options for gastric cancer?",
        "answer": "Output: Gastric cancer can be treated with the following drugs: 伏罗尼布, 仑伐替尼, 纳武利尤单抗, 帕博利珠单抗, 伊匹木单抗, 阿昔替尼, tivozanib, temsirolimus, and 替加氟."
    },
    {
        "question": "What is the relationship between BRAF gene mutation and the therapeutic effect of PLX8394?",
        "answer": "Output: BRAF gene mutation is the inhibition of PLX8394."
    },
    {
        "question": "Which genetic mutations may be related to the potential sensitivity of U3-1402?",
        "answer": "Output: The potential sensitivity of U3-1402 may be related to the following SNVs: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What is the relationship between BRCA2 gene mutation and the efficacy of talazoparib?",
        "answer": "Output: BRCA2 gene mutation is a synthetic lethality to talazoparib."
    },
    {
        "question": "How does EGFR affect the efficacy of panitumumab?",
        "answer": "Output: Panitumumab is inhibited by EGFR."
    },
    {
        "question": "What is the relationship between ERBB2 and the efficacy of trastuzumab?",
        "answer": "Output: Trastuzumab is an inhibitor of ERBB2."
    },
    {
        "question": "What is the relationship between MET and the efficacy of crizotinib?",
        "answer": "Output: Crizotinib is an inhibitor of MET."
    },
    {
        "question": "What is the relationship between ERBB2 and the dacomitinib?",
        "answer": "Output: dacomitinib is an inhibitor of ERBB2."
    },
    {
        "question": "With which cancers is the prognosis related to FGFR4?",
        "answer": "Output: The prognosis of FGFR4 is related to the following cancers: non-small cell lung cancer, renal cell carcinoma, and pancreatic cancer."
    },
    {
        "question": "How does EGFR gene mutation affect the efficacy of osimertinib?",
        "answer": "Output: Osimertinib is effective against EGFR gene mutation."
    },
    {
        "question": "What types of cancer can be treated with pembrolizumab?",
        "answer": "Output: Pembrolizumab can treat the following types of cancer: non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, gastroesophageal junction adenocarcinoma, stomach adenocarcinoma, pancreatic adenocarcinoma, and liver hepatocellular carcinoma."
    },
    {
        "question": "What is the relationship between FGFR1 and the nintedanib?",
        "answer": "Output: FGFR1 is inhibited by nintedanib."
    },
    {
        "question": "What is the relationship between BRAF gene mutation and the efficacy of osimertinib?",
        "answer": "Output: BRAF gene mutation is a driving force for the efficacy of osimertinib."
    },
    {
        "question": "What is the relationship between ERBB2 and the sapitinib?",
        "answer": "Output: sapitinib is an inhibitor of ERBB2."
    },
    {
        "question": "How does FLT3 affect the effectiveness of lestaurtinib?",
        "answer": "Output: Lestaurtinib inhibits FLT3."
    },
    {
        "question": "What is the relationship between MET gene mutation and the efficacy of merestinib?",
        "answer": "Output: MET gene mutation is inhibited by merestinib."
    },
    {
        "question": "Which genetic mutations may be related to the potential resistance of palbociclib?",
        "answer": "Output: The following snvfulls may be related to the potential resistance of palbociclib: CDK4-p.L125Q, CDK4-p.L147M, CDK4-p.K22R, CDK4-p.V37A, CDK4-p.V37L, CDK4-p.D140N, CDK4-p.A114D, CDK4-p.G13C, CDK4-p.H30R, CDK4-p.G111V."
    },
    {
        "question": "What types of cancer is tamoxifen related to?",
        "answer": "Output: Tamoxifen is related to breast cancer."
    },
    {
        "question": "Which genetic mutations are related to sensitivity to vemurafenib?",
        "answer": "Output: The following SNVs are related to sensitivity to vemurafenib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "Which genetic mutations need to be tested for sunitinib?",
        "answer": "Output: Sunitinib needs to be tested for the following SNVs: CSF1R-p.N788I, CSF1R-p.V116F, CSF1R-p.A503T, CSF1R-p.G182R, CSF1R-p.S55T, CSF1R-p.S190G, CSF1R-p.E554K, CSF1R-p.P147L, CSF1R-p.D802E, CSF1R-p.M804I."
    },
    {
        "question": "Which genetic mutations may be related to the potential resistance of crizotinib?",
        "answer": "Output: The following snvfulls may be related to the potential resistance of crizotinib: ALK-p.H1002R, ALK-p.G1402C, ALK-p.E766K, ALK-p.S413T, ALK-p.E1568D, ALK-p.A537G, ALK-p.N661I, ALK-p.Q453H, ALK-p.I725F, ALK-p.S237Y."
    },
    {
        "question": "Which genetic mutations need to be tested for dasatinib?",
        "answer": "Output: Dasatinib needs to be tested for the following SNVs: ABL1-p.V668I, ABL1-p.R483Q, ABL1-p.E466D, ABL1-p.G753A, ABL1-p.C1040W, ABL1-p.E540K, ABL1-p.R536W, ABL1-p.G182V, ABL1-p.A1082D, and ABL1-p.K838N."
    },
    {
        "question": "Which genetic mutations need to be tested for osimertinib?",
        "answer": "Output: Osimertinib needs to be tested for the following SNVs: EGFR-p.D807V, EGFR-p.A24S, EGFR-p.C240F, EGFR-p.Q1021K, EGFR-p.A750E, EGFR-p.R681K, EGFR-p.V60A, EGFR-p.G201C, EGFR-p.T382S, EGFR-p.V1011G."
    },
    {
        "question": "What types of cancer are the abiraterone related to?",
        "answer": "Output: Abiraterone is related to prostate cancer."
    },
    {
        "question": "What targeted drugs can be used for kidney with VHL gene mutation?",
        "answer": "Output: Kidney with VHL gene mutation can be treated with the following targeted drugs: nivolumab, pembrolizumab, ipilimumab, and alectinib."
    },
    {
        "question": "How does ALK affect the efficacy of lorlatinib?",
        "answer": "Output: Lorlatinib is inhibited by ALK."
    },
    {
        "question": "Which genetic mutations are associated with liver?",
        "answer": "Output: The following snvfulls are associated with liver: EGFR-p.L861R;EGFR-p.G719A;ERBB2-p.E401G;ALK-p.L1196M;MET-p.L1195V;CSF1R-p.Y546_K551del;MET-p.D1228N;CSF1R-p.W450_E456del;JAK2-p.V617F;ALK-p.L1198F."
    },
    {
        "question": "What is the relationship between BRAF gene mutation and colon cancer?",
        "answer": "Output: BRAF gene mutation is a driving force for colon cancer."
    },
    {
        "question": "Is there a correlation between PTEN and Wilson disease?",
        "answer": "Output: Yes, there is a correlation between PTEN and Wilson disease."
    },
    {
        "question": "What is the relationship between Familial Cerebral Cavernous Angioma and hemangioma?",
        "answer": "Output: Familial Cerebral Cavernous Angioma is a type of hemangioma."
    },
    {
        "question": "What is the relationship between NSD1 and Weaver syndrome?",
        "answer": "Output: NSD1 is a gene that causes Weaver syndrome."
    },
    {
        "question": "What types of cancer are associated with the FGFR2-p.E566G mutation?",
        "answer": "Output: The FGFR2-p.E566G mutation is associated with skin melanoma."
    },
    {
        "question": "What type of cancer can be driven by PIK3CA-p.H1047R?",
        "answer": "Output: PIK3CA-p.H1047R can drive breast cancer."
    },
    {
        "question": "What types of cancer are associated with ERBB2-act?",
        "answer": "Output: ERBB2-act is associated with the following types of cancer: breast cancer, ovarian cancer, and lung cancer."
    },
    {
        "question": "What class of drug does AT9283 belong to?",
        "answer": "Output: AT9283 belongs to the class of immunotherapy drugs."
    },
    {
        "question": "What type of drug does AZD3463 belong to?",
        "answer": "Output: AZD3463 belongs to the class of ALK inhibitors."
    },
    {
        "question": "What class of drug does altretamine belong to?",
        "answer": "Output: Altretamine belongs to the class of drug called ACE inhibitors."
    },
    {
        "question": "What category of drug does abiraterone belong to?",
        "answer": "Output: Abiraterone belongs to the category of androgen receptor antagonist."
    },
    {
        "question": "What types of cancer are associated with EGFR?",
        "answer": "Output: EGFR is associated with the following types of cancer: non-small cell lung cancer, renal cell carcinoma, and pancreatic cancer."
    },
    {
        "question": "What types of cancer is arsenic trioxide used to treat?",
        "answer": "Output: Arsenic trioxide is used to treat acute myeloid leukemia (AML)."
    },
    {
        "question": "What types of cancer is alitretinoin used to treat?",
        "answer": "Output: Alitretinoin is used to treat renal cell carcinoma."
    },
    {
        "question": "What targeted drugs can be used for CLIP1 mutation in clear cell carcinoma of the lung?",
        "answer": "Output: The targeted drug for CLIP1 mutation in clear cell carcinoma of the lung is lenvatinib."
    },
    {
        "question": "What types of cancer can aclarubicin treat?",
        "answer": "Output: Aclarubicin can treat acute lymphoblastic leukemia."
    },
    {
        "question": "What types of cancer can be treated with bendamustine?",
        "answer": "Output: Bendamustine can be used to treat non-Hodgkin lymphoma, Hodgkin lymphoma, and small cell lung cancer."
    },
    {
        "question": "What types of cancer is altretamine suitable for treating?",
        "answer": "Output: Altretamine is suitable for treating renal cell carcinoma."
    },
    {
        "question": "What types of cancer can amg-510(racemate) treat?",
        "answer": "Output: Amg-510(racemate) can treat renal cell carcinoma."
    },
    {
        "question": "Which types of cancer are related to the JUB gene?",
        "answer": "Output: The JUB gene is related to the following types of cancer: renal cell carcinoma, pancreatic neuroendocrine tumors, and pancreatic cancer."
    },
    {
        "question": "How to treat cholangiocarcinoma carrying FGFR2?",
        "answer": "Output: Cholangiocarcinoma carrying FGFR2 can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat uterus carrying NTRK1 fusion gene mutation?",
        "answer": "Output: Uterus carrying NTRK1 fusion gene mutation can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What is the relationship between EGFR and ramucirumab?",
        "answer": "Output: EGFR is a driving gene to non-small cell lung cancer, and ramucirumab is a treatment option for non-small cell lung cancer."
    },
    {
        "question": "In which types of cancer is the SND1-BRAF found?",
        "answer": "Output: SND1-BRAF is found in the following types of cancer: melanoma, lung cancer, and breast cancer."
    },
    {
        "question": "In which types of cancer does the KMT2A-MLLT1 occur?",
        "answer": "Output: KMT2A-MLLT1 occurs in the following types of cancer: breast cancer, lung cancer, and ovarian cancer."
    },
    {
        "question": "Which genetic mutations need to be tested for ceritinib?",
        "answer": "Output: The following snvfulls need to be tested for ceritinib: ALK-p.H1002R, ALK-p.G1402C, ALK-p.E766K, ALK-p.S413T, ALK-p.E1568D, ALK-p.A537G, ALK-p.N661I, ALK-p.Q453H, ALK-p.I725F, ALK-p.S237Y."
    },
    {
        "question": "Which genetic mutations are possibly related to sensitivity to dovitinib?",
        "answer": "Output: The following SNVs are possibly related to sensitivity to dovitinib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "How does a RET gene mutation affect the efficacy of selpercatinib?",
        "answer": "Output: Selpercatinib is inhibited by RET gene mutation."
    },
    {
        "question": "What genetic mutations need to be detected for zanidatamab?",
        "answer": "Output: Zanidatamab needs to be detected for the following snvs: ERBB2-p.P1106S, ERBB2-p.V669M, ERBB2-p.Q984P, ERBB2-p.E405D, ERBB2-p.F1030V, ERBB2-p.A293D, ERBB2-p.I767V, ERBB2-p.E892*, ERBB2-p.S893C, ERBB2-c.574+1G>A."
    },
    {
        "question": "What types of cancer can be treated with carboplatin?",
        "answer": "Output: Carboplatin can be used to treat the following types of cancer: ovarian cancer, pancreatic cancer, and renal cell carcinoma."
    },
    {
        "question": "Which genetic mutations are related to sensitivity to talazoparib?",
        "answer": "Output: The following SNVs are related to sensitivity to talazoparib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What are the drug treatment options for peritoneal mesothelioma?",
        "answer": "Output: Peritoneal mesothelioma can be treated with the following drugs: temozolomide, gemcitabine, carboplatin, paclitaxel, and docetaxel."
    },
    {
        "question": "How does FGFR1 affect the efficacy of ponatinib?",
        "answer": "Output: Ponatinib inhibits the activity of FGFR1, which enhances the efficacy of FGFR1."
    },
    {
        "question": "Which genetic mutations are related to potential resistance to trametinib?",
        "answer": "Output: The following snvfulls are related to potential resistance to trametinib: MAP2K1-p.D67A, MAP2K1-p.K59R, MAP2K1-p.S135G, MAP2K1-p.E102D, MAP2K1-p.E41A, MAP2K1-p.P262L, MAP2K1-p.G213R, MAP2K1-p.G75A, MAP2K1-p.L215I, MAP2K1-p.G380D."
    },
    {
        "question": "Which genetic mutations are related to sensitivity to everolimus?",
        "answer": "Output: The following SNVs are related to sensitivity to everolimus: ALK-p.F1245C-巨细胞肺癌, ALK-p.L1196M-巨细胞肺癌, ALK-p.C1156Y-巨细胞肺癌, ALK-p.F1174V-巨细胞肺癌, ALK-p.C1156Y-巨细胞肺癌, CMTR1-ALK-巨细胞肺癌."
    },
    {
        "question": "How does EWSR1 affect the efficacy of seclidemstat?",
        "answer": "Output: EWSR1 is a negative regulator of seclidemstat."
    },
    {
        "question": "How does ERBB2 affect the efficacy of treatment with pembrolizumab?",
        "answer": "Output: Pembrolizumab is effective in treating renal cell carcinoma that is ERBB2-positive."
    },
    {
        "question": "What drugs can treat cancers with FGFR3 mutations?",
        "answer": "Output: FGFR3-carrying tumors can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How does EGFR gene mutation affect the efficacy of amivantamab-vmjw?",
        "answer": "Output: EGFR gene mutation can affect the efficacy of amivantamab-vmjw."
    },
    {
        "question": "How to treat skin with NRAS?",
        "answer": "Output: The drug ibrutinib can be used to treat skin with NRAS."
    },
    {
        "question": "How does RET gene mutation affect the efficacy of vandetanib?",
        "answer": "Output: Vandetanib is inhibited by RET gene mutation."
    },
    {
        "question": "Which genetic mutations need to be tested for afatinib?",
        "answer": "Output: Afatinib needs to be tested for the following SNVs: EGFR-p.D807V, EGFR-p.A24S, EGFR-p.C240F, EGFR-p.Q1021K, EGFR-p.A750E, EGFR-p.R681K, EGFR-p.V60A, EGFR-p.G201C, EGFR-p.T382S, and EGFR-p.V1011G."
    },
    {
        "question": "Which genetic mutations may be related to sensitivity to vemurafenib?",
        "answer": "Output: The following SNVs may be related to sensitivity to vemurafenib: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What is the relationship between BRAF and panitumumab?",
        "answer": "Output: BRAF is a synthetic lethality of EGFR, and panitumumab is an inhibition to EGFR."
    },
    {
        "question": "What is the relationship between BRCA1 gene mutation and olaparib?",
        "answer": "Output: Olaparib is a gene mutation inhibitor of BRCA1 gene."
    },
    {
        "question": "What is the relationship between the ALK and the crizotinib?",
        "answer": "Output: ALK is inhibited by crizotinib."
    },
    {
        "question": "What is the relationship between HRAS and the efficacy of selumetinib?",
        "answer": "Output: Selumetinib inhibits the activity of HRAS, and the activity of HRAS is positively regulated by MAP2K1 and MAP2K2."
    },
    {
        "question": "How to treat non-small cell lung cancer with EGFR mutation?",
        "answer": "Output: For EGFR mutation non-small cell lung cancer, treat with atezolizumab, pembrolizumab, and nivolumab."
    },
    {
        "question": "How to treat colon adenocarcinoma with POMK?",
        "answer": "Output: Colon adenocarcinoma can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat small cell carcinoma of the ovary carrying EML4?",
        "answer": "Output: Small cell carcinoma of the ovary carrying EML4 can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What types of cancer can be treated with atezolizumab?",
        "answer": "Output: Atezolizumab can be used to treat the following types of cancer: non-small cell lung cancer, gastric cancer, stomach cancer, pancreatic cancer, liver cancer, kidney cancer, and lung cancer."
    },
    {
        "question": "Which genetic mutations need to be tested for sorafenib?",
        "answer": "Output: Sorafenib needs to be tested for the following SNVs: CSF1R-p.N788I, CSF1R-p.V116F, CSF1R-p.A503T, CSF1R-p.G182R, CSF1R-p.S55T, CSF1R-p.S190G, CSF1R-p.E554K, CSF1R-p.P147L, CSF1R-p.D802E, and CSF1R-p.M804I."
    },
    {
        "question": "How does the BRCA2 affect the efficacy of talazoparib?",
        "answer": "Output: Talazoparib is a PARP inhibitor that can effectively inhibit the activity of PARP1 and PARP2, which can reduce the efficacy of BRCA2."
    },
    {
        "question": "What is the relationship between EGFR and anlotinib?",
        "answer": "Output: Anlotinib is a inhibitor of EGFR."
    },
    {
        "question": "Which genetic mutations need to be tested for selumetinib?",
        "answer": "Output: Selumetinib needs to be tested for the following snvfulls: MAP2K1-p.D67A, MAP2K1-p.K59R, MAP2K1-p.S135G, MAP2K1-p.E102D, MAP2K1-p.E41A, MAP2K1-p.P262L, MAP2K1-p.G213R, MAP2K1-p.G75A, MAP2K1-p.L215I, MAP2K1-p.G380D."
    },
    {
        "question": "What genetic mutations need to be detected for dovitinib?",
        "answer": "Output: Dovitinib needs to be detected with the following SNVs: CSF1R-p.N788I, CSF1R-p.V116F, CSF1R-p.A503T, CSF1R-p.G182R, CSF1R-p.S55T, CSF1R-p.S190G, CSF1R-p.E554K, CSF1R-p.P147L, CSF1R-p.D802E, CSF1R-p.M804I."
    },
    {
        "question": "Which genetic mutations are related to possible resistance to dabrafenib?",
        "answer": "Output: The following snvfulls are related to possible resistance to dabrafenib: BRAF-p.Q530H, BRAF-p.R603L, BRAF-p.Q709*, BRAF-p.Q524P, BRAF-p.R691I, BRAF-p.S447N, BRAF-p.Q201*, BRAF-p.N163Y, BRAF-p.L588I, BRAF-p.A305V."
    },
    {
        "question": "How to treat pleura with NTRK1?",
        "answer": "Output: NTRK1 in pleura can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat non-small cell lung cancer with EGFR?",
        "answer": "Output: Non-small cell lung cancer with EGFR can be treated with the following drugs: gefitinib, erlotinib, afatinib, osimertinib, and lenvatinib."
    },
    {
        "question": "How does the ROS1 affect the efficacy of crizotinib?",
        "answer": "Output: Crizotinib is inhibited by ROS1."
    },
    {
        "question": "How to treat lung adenosquamous carcinoma carrying ALK?",
        "answer": "Output: For lung adenosquamous carcinoma carrying ALK, the treatment options are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What is the relationship between EGFR and the icotinib?",
        "answer": "Output: EGFR is inhibited by icotinib."
    },
    {
        "question": "What is the relationship between BRAF and the efficacy of vemurafenib?",
        "answer": "Output: BRAF inhibits the efficacy of vemurafenib."
    },
    {
        "question": "How to treat biliary tract with RET mutation?",
        "answer": "Output: The treatment options for biliary tract with RET mutation are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat uterus carrying PIK3CA?",
        "answer": "Output: The treatment options for uterus carrying PIK3CA are: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How does FGFR1 affect the efficacy of pazopanib?",
        "answer": "Output: Pazopanib is inhibited by FGFR1."
    },
    {
        "question": "How does EGFR affect the efficacy of gefitinib?",
        "answer": "Output: Gefitinib is effective against EGFR."
    },
    {
        "question": "What is the relationship between BRAF and sorafenib?",
        "answer": "Output: BRAF is driving to 甲状腺癌, and 甲状腺癌 is treated by sorafenib."
    },
    {
        "question": "How does a mutation in the BRCA1 gene affect the efficacy of talazoparib?",
        "answer": "Output: Talazoparib can inhibit the activity of PARP1 and PARP2, which are mutated in BRCA1, and reduce the efficacy of BRCA1."
    },
    {
        "question": "How to treat pancreatic adenocarcinoma with KRAS?",
        "answer": "Output: Pancreatic adenocarcinoma with KRAS can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How does KIT affect the effectiveness of imatinib?",
        "answer": "Output: KIT regulates the effectiveness of imatinib."
    },
    {
        "question": "How to treat non-small cell lung cancer with ERBB2 mutation?",
        "answer": "Output: Non-small cell lung cancer with ERBB2 mutation can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What is the relationship between KIT and the effectiveness of imatinib?",
        "answer": "Output: KIT is inhibited by imatinib."
    },
    {
        "question": "How does the ALK affect the efficacy of lorlatinib?",
        "answer": "Output: Lorlatinib is inhibited by ALK."
    },
    {
        "question": "How to treat uterine undifferentiated carcinoma with PTEN?",
        "answer": "Output: Uterine undifferentiated carcinoma with PTEN can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How does BRAF affect the effectiveness of dabrafenib?",
        "answer": "Output: Dabrafenib is inhibited by BRAF."
    },
    {
        "question": "How to treat uterine mucinous carcinoma carrying AKT1?",
        "answer": "Output: For uterine mucinous carcinoma carrying AKT1, treatment options include cobimetinib, crizotinib, and ruxolitinib."
    },
    {
        "question": "How to treat endometrioid carcinoma with PIK3CA?",
        "answer": "Output: PIK3CA-positive endometrioid carcinoma can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How does MET affect the efficacy of capmatinib?",
        "answer": "Output: Capmatinib inhibits the efficacy of MET."
    },
    {
        "question": "How to treat non-small cell lung cancer with BRAF?",
        "answer": "Output: Non-small cell lung cancer with BRAF can be treated with the following drugs: vemurafenib, dabrafenib, crizotinib, and nivolumab."
    },
    {
        "question": "How does EGFR affect the efficacy of rociletinib?",
        "answer": "Output: Rociletinib inhibits the efficacy of EGFR."
    },
    {
        "question": "How does a PDGFRA affect the efficacy of imatinib?",
        "answer": "Output: PDGFRA inhibits the efficacy of imatinib."
    },
    {
        "question": "How to treat melanoma with NRAS?",
        "answer": "Output: Melanoma with NRAS can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat non-small cell lung cancer with EGFR?",
        "answer": "Output: Non-small cell lung cancer with EGFR can be treated with the following drugs: gefitinib, erlotinib, afatinib, osimertinib, and lenvatinib."
    },
    {
        "question": "How to treat brenner tumor carrying TP53?",
        "answer": "Output: Brenner tumor carrying TP53 can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What types of cancer are associated with sorafenib?",
        "answer": "Output: Sorafenib is associated with renal cell carcinoma, hepatocellular carcinoma, and pancreatic neuroendocrine tumors."
    },
    {
        "question": "How does EGFR gene mutation affect the efficacy of osimertinib?",
        "answer": "Output: Osimertinib is effective against EGFR mutations."
    },
    {
        "question": "How does EGFR gene mutation affect the efficacy of afatinib?",
        "answer": "Output: EGFR gene mutation affects the efficacy of afatinib."
    },
    {
        "question": "How to treat salivary gland-type tumor of the lung carrying FGFR2?",
        "answer": "Output: The treatment of salivary gland-type tumor of the lung carrying FGFR2 is lenvatinib."
    },
    {
        "question": "How does BRAF affect the vemurafenib?",
        "answer": "Output: BRAF inhibits the vemurafenib."
    },
    {
        "question": "What are the fusion genes in angiomatoid fibrous histiocytoma?",
        "answer": "Output: The fusion genes in angiomatoid fibrous histiocytoma are ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK, and ALK-p.F1245C."
    },
    {
        "question": "How does the BRAF gene mutation affect the therapeutic effect of trametinib?",
        "answer": "Output: The BRAF gene mutation can inhibit the therapeutic effect of trametinib."
    },
    {
        "question": "How does the MET gene mutation affect the efficacy of tepotinib?",
        "answer": "Output: The MET gene mutation can inhibit the efficacy of tepotinib."
    },
    {
        "question": "How would you describe hepatobiliary tumor?",
        "answer": "Output: Hepatobiliary tumor is a type of cancer that develops in the liver or gallbladder."
    },
    {
        "question": "How would you describe SC Phocomelia syndrome?",
        "answer": "Output: SC Phocomelia syndrome is a rare genetic disorder that affects the development of the limbs and face, and is characterized by limb deformities and facial abnormalities."
    },
    {
        "question": "How would you describe Schwannomatosis?",
        "answer": "Output: Schwannomatosis is a rare genetic disorder that affects the nervous system, characterized by multiple benign tumors in the skin, central nervous system tumors, and neurological abnormalities."
    },
    {
        "question": "How would you describe Hereditary Desmoid Disease?",
        "answer": "Output: Hereditary Desmoid Disease is a rare genetic disorder that affects the gastrointestinal tract and is characterized by the presence of benign tumors."
    },
    {
        "question": "How would you describe Galactosemia?",
        "answer": "Output: Galactosemia is a rare genetic disorder that affects the body's ability to break down the sugar called galactose. It can cause symptoms such as vomiting, diarrhea, weight loss, and fatigue. In severe cases, it can lead to liver damage and liver failure."
    },
    {
        "question": "How would you describe ezatiostat?",
        "answer": "Output: Ezatiostat is a GST P1-1 inhibitor that activates Jun and MAPK pathways to promote cell proliferation and differentiation."
    },
    {
        "question": "How would you describe alectinib?",
        "answer": "Output: Alectinib is a drug that targets ALK and RET. Non-clinical studies suggest that alectinib can inhibit ALK phosphorylation and activate STAT3 and AKT proteins, and it can reduce the survival of cancer cells with ALK fusion, ALK gene amplification or ALK gene mutation. The main active metabolite of alectinib (M4) has similar in vivo activity and activity as alectinib. Alectinib and M4 both have inhibitory activity against multiple ALK mutations, including those identified in patients, and have inhibitory activity against ALK-driven cancer cells in ALK fusion gene-transfected mouse models."
    },
    {
        "question": "How would you describe durvalumab?",
        "answer": "Output: Durvalumab is a human immunoglobulin G1κ (IgG1κ) single-chain variable fragment (scFv) antibody that can bind to PD-L1 and inhibit its interaction with PD-1 and CD80, thereby suppressing the activation of T cells and enhancing the activity of T cells."
    },
    {
        "question": "How would you describe enocitabine?",
        "answer": "Output: Enocitabine is a DNA-based drug that can inhibit the replication of human papillomavirus and has antiviral and anticancer effects."
    },
    {
        "question": "How would you describe gandotinib?",
        "answer": "Output: Gandotinib is a JAK2 V617F inhibitor that can selectively inhibit JAK2 V617F-mediated activation and induce JAK2 V617F-dependent cell death in cancer cells."
    },
    {
        "question": "How would you describe fentanyl?",
        "answer": "Output: Fentanyl is a potent and fast-acting opioid analgesic that is used to treat severe pain. It has a short duration of action and is not addictive."
    },
    {
        "question": "How would you describe intestinal ampullary carcinoma?",
        "answer": "Output: Intestinal ampullary carcinoma is a type of cancer that develops in the intestine, usually in the ampulla of the colon. It is a rare type of cancer that can be difficult to diagnose."
    },
    {
        "question": "How would you describe adrenal gland?",
        "answer": "Output: The adrenal gland is a glandular organ located on the top of the kidneys. It produces hormones that help regulate blood pressure, heart rate, and metabolism."
    },
    {
        "question": "How would you describe bowel?",
        "answer": "Output: Bowel refers to the large intestine."
    },
    {
        "question": "What are the genetic mutations in PLAG1?",
        "answer": "Output: PLAG1 has the following SNVs: PLAG1-p.L1196M, PLAG1-p.C1156Y, PLAG1-p.F1174V, PLAG1-p.C1156Y, PLAG1-p.F1245C, and PLAG1-p.C1156Y."
    },
    {
        "question": "What are the genetic mutations in ZFHX3?",
        "answer": "Output: ZFHX3 has the following SNVs: p.G12C, p.G12D, p.G12E, p.G12F, p.G12H, p.G12I, p.G12J, p.G12K, p.G12L, p.G12M, p.G12N, p.G12O, p.G12P, p.G12Q, p.G12R, p.G12S, p.G12T, p.G12U, p.G12V, p.G12W, p.G12X, p.G12Y, p.G12Z, p.G12a, p.G12b, p.G12c, p.G12d, p.G12e, p.G12f, p.G12g, p.G12h, p.G12i, p.G12j, p.G12k, p.G12l, p.G12m, p.G12n, p.G12o, p.G12p, p.G12q, p.G12r, p.G12s, p.G12t, p.G12u, p.G12v, p.G12w, p.G12x, p.G12y, p.G12z, p.G12A, p.G12B, p.G12C, p.G12D, p.G12E, p.G12F, p.G12G, p.G12H, p.G12I, p.G12J, p.G12K, p.G12L, p.G12M, p.G12N, p.G12O, p.G12P, p.G12Q, p.G12R, p.G12S, p.G12T, p.G12U, p.G12V, p.G12W, p.G12X, p.G12Y, p.G12Z, p.G12a, p.G12b, p.G12c, p.G12d, p.G12e, p.G12f, p.G12g, p.G12h, p.G12i, p.G12j, p.G12k, p.G12l, p.G12m, p.G12n, p.G12o, p.G12p, p.G12q, p.G12r, p.G12s, p.G12t, p.G12u, p.G12v, p.G12w, p.G12x, p.G12y, p.G12z, p.G12A, p.G12B, p.G12C, p.G12D, p.G12E, p.G12F, p.G12G, p.G12H, p.G12I, p.G12J, p.G12K, p.G12L, p.G12M, p.G12N, p.G12O, p.G12P, p.G12Q, p.G12R, p.G12S, p.G12T, p.G12U, p.G12V, p.G12W, p.G12X, p.G12Y, p.G12Z, p.G12a, p.G12b, p.G12c, p.G12d, p.G12e, p.G12f, p.G12g, p.G12h, p.G12i, p.G12j, p.G12k, p.G12l, p.G12m, p.G12n, p.G12o, p.G12p, p.G12q, p.G12r, p.G12s, p.G12t, p.G12u, p.G12v, p.G12w, p.G12x, p.G12y, p.G12z, p.G12A, p.G12B, p.G12C, p.G12D, p.G12E, p.G12F, p.G12G, p.G12H, p.G12I, p.G12J, p.G12K, p.G12L, p.G12M, p.G12N, p.G12O, p.G12P, p.G12Q, p.G12R, p.G12S, p.G12T, p.G12U, p.G12V, p.G12W, p.G12X, p.G12Y, p.G12Z, p.G12a, p.G12b, p.G12c, p.G12d, p.G12e, p.G12f, p.G12g, p.G12h, p.G12i, p.G12j, p.G12k, p.G12l, p.G12m, p.G12n, p.G12o, p.G12p, p.G12q, p.G12r, p.G12s, p.G12t, p.G12u, p.G12v, p.G12w, p.G12x, p.G12y, p.G12z, p.G12A, p.G12B, p.G12C, p.G12D, p.G12E, p.G12F, p.G12G, p.G12H, p.G12I, p.G12J, p.G12K, p.G12L, p.G12M, p.G12N, p.G12O, p.G12P, p.G12Q, p.G12R, p.G12S, p.G12T, p.G12U, p.G12V, p.G12W, p.G12X, p.G12Y, p.G12Z, p.G12a, p.G12b, p.G12c, p.G12d, p.G12e, p.G12f"
    },
    {
        "question": "What are the genetic mutations in PTPRD?",
        "answer": "Output: PTPRD has the following snvfulls: PTPRD-p.L1196M, PTPRD-p.C1156Y, PTPRD-p.F1174V, PTPRD-p.C1156Y, PTPRD-p.F1245C, and PTPRD-p.C1156Y."
    },
    {
        "question": "What are the genetic mutations in CARD11?",
        "answer": "Output: CARD11 has the following SNVs: C1156Y, F1245C, F1174V, L1196M, and C1156Y."
    },
    {
        "question": "What are the genetic mutations in NBEA?",
        "answer": "Output: NBEA has the following SNVs: ALK-p.L1196M, ALK-p.C1156Y, ALK-p.F1174V, ALK-p.C1156Y, ALK-p.F1245C, CMTR1-ALK."
    },
    {
        "question": "What are the genetic mutations in PCDH17?",
        "answer": "Output: PCDH17 has the following SNVs: PCDH17-p.R104W, PCDH17-p.R104H, PCDH17-p.R104Q, PCDH17-p.R104L, PCDH17-p.R104F, PCDH17-p.R104S, PCDH17-p.R104T, PCDH17-p.R104C, PCDH17-p.R104M, PCDH17-p.R104I, PCDH17-p.R104V, PCDH17-p.R104A, PCDH17-p.R104D, PCDH17-p.R104G, PCDH17-p.R104Y, PCDH17-p.R104N, PCDH17-p.R104K, PCDH17-p.R104E, PCDH17-p.R104B, PCDH17-p.R104Z, PCDH17-p.R104X, PCDH17-p.R104P, PCDH17-p.R104O, PCDH17-p.R104U, PCDH17-p.R104J, PCDH17-p.R104H, PCDH17-p.R104R, PCDH17-p.R104W, PCDH17-p.R104S, PCDH17-p.R104T, PCDH17-p.R104C, PCDH17-p.R104M, PCDH17-p.R104I, PCDH17-p.R104V, PCDH17-p.R104A, PCDH17-p.R104D, PCDH17-p.R104G, PCDH17-p.R104Y, PCDH17-p.R104N, PCDH17-p.R104K, PCDH17-p.R104E, PCDH17-p.R104B, PCDH17-p.R104Z, PCDH17-p.R104X, PCDH17-p.R104P, PCDH17-p.R104O, PCDH17-p.R104U, PCDH17-p.R104J, PCDH17-p.R104H, PCDH17-p.R104R, PCDH17-p.R104W, PCDH17-p.R104S, PCDH17-p.R104T, PCDH17-p.R104C, PCDH17-p.R104M, PCDH17-p.R104I, PCDH17-p.R104V, PCDH17-p.R104A, PCDH17-p.R104D, PCDH17-p.R104G, PCDH17-p.R104Y, PCDH17-p.R104N, PCDH17-p.R104K, PCDH17-p.R104E, PCDH17-p.R104B, PCDH17-p.R104Z, PCDH17-p.R104X, PCDH17-p.R104P, PCDH17-p.R104O, PCDH17-p.R104U, PCDH17-p.R104J, PCDH17-p.R104H, PCDH17-p.R104R, PCDH17-p.R104W, PCDH17-p.R104S, PCDH17-p.R104T, PCDH17-p.R104C, PCDH17-p.R104M, PCDH17-p.R104I, PCDH17-p.R104V, PCDH17-p.R104A, PCDH17-p.R104D, PCDH17-p.R104G, PCDH17-p.R104Y, PCDH17-p.R104N, PCDH17-p.R104K, PCDH17-p.R104E, PCDH17-p.R104B, PCDH17-p.R104Z, PCDH17-p.R104X, PCDH17-p.R104P, PCDH17-p.R104O, PCDH17-p.R104U, PCDH17-p.R104J, PCDH17-p.R104H, PCDH17-p.R104R, PCDH17-p.R104W, PCDH17-p.R104S, PCDH17-p.R104T, PCDH17-p.R104C, PCDH17-p.R104M, PCDH17-p.R104I, PCDH17-p.R104V, PCDH17-p.R104A, PCDH17-p.R104D, PCDH17-p.R104G, PCDH17-p.R104Y, PCDH17-p.R104N, PCDH17-p.R104K, PCDH17-p.R104E, PCDH17-p.R104B, PCDH17-p.R104Z, PCDH17-p.R104X, PCDH17-p.R104P, PCDH17-p.R104O, PCDH17-p.R104U, PCDH17-p.R104J, PCDH17-p.R104H, PCDH17-"
    },
    {
        "question": "Which type of cancer is likely to be driven by HIP1?",
        "answer": "Output: The type of cancer that is likely to be driven by HIP1 is renal cell carcinoma."
    },
    {
        "question": "Which type of cancer is likely to be driven by ZNRF3?",
        "answer": "Output: Renal cell carcinoma is likely to be driven by ZNRF3."
    },
    {
        "question": "What kind of cancer can be driven by H3F3A?",
        "answer": "Output: H3F3A can drive high-grade epithelial tumors, non-specific."
    },
    {
        "question": "What kind of cancer can be driven by PLAG1?",
        "answer": "Output: PLAG1 can drive breast cancer."
    },
    {
        "question": "What kind of cancer can be driven by ZNF148?",
        "answer": "Output: ZNF148 can drive the development of renal cell carcinoma."
    },
    {
        "question": "What kind of cancer can be driven by BCL9?",
        "answer": "Output: BCL9 can drive the following types of cancer: colon cancer, pancreatic cancer, and renal cell cancer."
    },
    {
        "question": "What kind of cancer can be driven by PCDH17?",
        "answer": "Output: PCDH17 can drive pancreatic cancer."
    },
    {
        "question": "What kind of cancer could Bloom syndrome eventually develop to?",
        "answer": "Output: Bloom syndrome may eventually develop to the following types of cancer: Wilms tumor, renal cell carcinoma, skin cancer, oral cancer, laryngeal cancer, liver cancer, gastric cancer, colon cancer, cervical cancer, breast cancer."
    },
    {
        "question": "What kind of cancer could Denys-Drash syndrome eventually develop to?",
        "answer": "Output: Denys-Drash syndrome may eventually develop to renal cell carcinoma."
    },
    {
        "question": "What kind of cancer could Tumor predisposition syndrome eventually develop to?",
        "answer": "Output: Tumor predisposition syndrome may eventually develop to renal cell carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, pancreatic ductal carcinoma,"
    },
    {
        "question": "What kind of cancer could Schwannomatosis eventually develop to?",
        "answer": "Output: Schwannomatosis may eventually develop into a type of brain tumor called glioma."
    },
    {
        "question": "What kind of cancer could Hereditary Desmoid Disease eventually develop to?",
        "answer": "Output: Hereditary Desmoid Disease may eventually develop to colon cancer."
    },
    {
        "question": "What kind of cancer could Alagille Syndrome eventually develop to?",
        "answer": "Output: Alagille Syndrome may develop to renal cell carcinoma."
    },
    {
        "question": "What cancer will Li-Fraumeni syndrome develop into?",
        "answer": "Output: Li-Fraumeni syndrome will develop into renal cell carcinoma."
    },
    {
        "question": "What cancer will Sotos syndrome develop into?",
        "answer": "Output: Sotos syndrome will develop into Wilms tumor."
    },
    {
        "question": "What cancer will RAPADILINO syndrome develop into?",
        "answer": "Output: RAPADILINO syndrome will develop into renal cell carcinoma."
    },
    {
        "question": "What cancer will Baller-Gerold syndrome develop into?",
        "answer": "Output: Baller-Gerold syndrome will develop into lymphoma."
    },
    {
        "question": "What is the relationship between Steatocystoma Multiplex and sebaceous carcinoma?",
        "answer": "Output: Steatocystoma multiplex is a type of sebaceous carcinoma."
    },
    {
        "question": "What is the relationship between Hereditary Diffuse Gastric Cancer and gastric cancer?",
        "answer": "Output: Hereditary Diffuse Gastric Cancer is a type of gastric cancer."
    },
    {
        "question": "What is the relationship between Ataxia Telangiectasia and ATM?",
        "answer": "Output: Ataxia Telangiectasia is caused by ATM."
    },
    {
        "question": "What is the relationship between Macrocephaly-Cutis Marmorata syndrome and PIK3CA?",
        "answer": "Output: Macrocephaly-Cutis Marmorata syndrome is caused by PIK3CA."
    },
    {
        "question": "What is the relationship between Hereditary Desmoid Disease and APC?",
        "answer": "Output: Hereditary Desmoid Disease is caused by APC."
    },
    {
        "question": "What is the relationship between Juvenile Polyposis and BMPR1A?",
        "answer": "Output: Juvenile Polyposis is caused by BMPR1A."
    },
    {
        "question": "What is the relationship between Mosaic Variegated Aneuploidy Syndrome and BUB1B?",
        "answer": "Output: Mosaic Variegated Aneuploidy Syndrome is caused by BUB1B."
    },
    {
        "question": "What is the relationship between Beckwith-Wiedemann syndrome and CDKN1C?",
        "answer": "Output: Beckwith-Wiedemann syndrome is caused by CDKN1C."
    },
    {
        "question": "What diseases can WAS lead to?",
        "answer": "Output: WAS can lead to Wiskott-Aldrich syndrome."
    },
    {
        "question": "What diseases can MTAP gene mutation lead to?",
        "answer": "Output: MTAP gene mutation can lead to the following diseases: Bone Dysplasia with Malignant Change."
    },
    {
        "question": "What diseases can be caused by mutations in the AR gene?",
        "answer": "Output: The diseases caused by mutations in the AR gene include Androgen Receptor-Positive Prostate Cancer, Androgen Receptor-Negative Prostate Cancer, Androgen Receptor-Positive Breast Cancer, Androgen Receptor-Negative Breast Cancer, Androgen Receptor-Positive Lung Cancer, Androgen Receptor-Negative Lung Cancer, Androgen Receptor-Positive Colorectal Cancer, Androgen Receptor-Negative Colorectal Cancer, Androgen Receptor-Positive Pancreatic Cancer, Androgen Receptor-Negative Pancreatic Cancer, Androgen Receptor-Positive Liver Cancer, Androgen Receptor-Negative Liver Cancer, Androgen Receptor-Positive Kidney Cancer, Androgen Receptor-Negative Kidney Cancer, Androgen Receptor-Positive Bladder Cancer, Androgen Receptor-Negative Bladder Cancer, Androgen Receptor-Positive Ovarian Cancer, Androgen Receptor-Negative Ovarian Cancer, Androgen Receptor-Positive Uterine Cancer, Androgen Receptor-Negative Uterine Cancer, Androgen Receptor-Positive Endometrial Cancer, Androgen Receptor-Negative Endometrial Cancer, Androgen Receptor-Positive Thyroid Cancer, Androgen Receptor-Negative Thyroid Cancer, Androgen Receptor-Positive Testicular Cancer, Androgen Receptor-Negative Testicular Cancer, Androgen Receptor-Positive Brain Cancer, Androgen Receptor-Negative Brain Cancer, Androgen Receptor-Positive Melanoma, Androgen Receptor-Negative Melanoma, Androgen Receptor-Positive Leukemia, Androgen Receptor-Negative Leukemia, Androgen Receptor-Positive Lymphoma, Androgen Receptor-Negative Lymphoma, Androgen Receptor-Positive Myeloma, Androgen Receptor-Negative Myeloma, Androgen Receptor-Positive Adenocarcinoma, Androgen Receptor-Negative Adenocarcinoma, Androgen Receptor-Positive Squamous Cell Carcinoma, Androgen Receptor-Negative Squamous Cell Carcinoma, Androgen Receptor-Positive Basal Cell Carcinoma, Androgen Receptor-Negative Basal Cell Carcinoma, Androgen Receptor-Positive Papillary Carcinoma, Androgen Receptor-Negative Papillary Carcinoma, Androgen Receptor-Positive Clear Cell Carcinoma, Androgen Receptor-Negative Clear Cell Carcinoma, Androgen Receptor-Positive Adenoma, Androgen Receptor-Negative Adenoma, Androgen Receptor-Positive Carcinoma, Androgen Receptor-Negative Carcinoma, Androgen Receptor-Positive Tumor, Androgen Receptor-Negative Tumor, Androgen Receptor-Positive Cancer, Androgen Receptor-Negative Cancer, Androgen Receptor-Positive Disease, Androgen Receptor-Negative Disease, Androgen Receptor-Positive Syndrome, Androgen Receptor-Negative Syndrome, Androgen Receptor-Positive Disorder, Androgen Receptor-Negative Disorder, Androgen Receptor-Positive Diseases, Androgen Receptor-Negative Diseases, Androgen Receptor-Positive Syndromes, Androgen Receptor-Negative Syndromes, Androgen Receptor-Positive Disorders, Androgen Receptor-Negative Disorders, Androgen Receptor-Positive Diseases, Androgen Receptor-Negative Diseases, Androgen Receptor-Positive Syndromes, Androgen Receptor-Negative Syndromes, Androgen Receptor-Positive Disorders, Androgen Receptor-Negative Disorders, Androgen Receptor-Positive Diseases, Androgen Receptor-Negative Diseases, Androgen Receptor-Positive"
    },
    {
        "question": "What diseases can be caused by mutations in the PHB gene?",
        "answer": "Output: The PHB gene mutations can cause breast cancer, ovarian cancer, and other diseases."
    },
    {
        "question": "What diseases can be caused by mutations in the PALB2?",
        "answer": "Output: PALB2 mutations can cause cancer, and the most common cancer caused by PALB2 mutations is osteosarcoma."
    },
    {
        "question": "What diseases can be caused by mutations in the BLM?",
        "answer": "Output: The following diseases can be caused by mutations in the BLM: Bloom syndrome, leukemia, lymphoma, colon cancer, breast cancer, basal cell carcinoma, oral cancer, esophageal cancer, stomach cancer, pancreatic cancer."
    },
    {
        "question": "What diseases can be caused by mutations in the WT1?",
        "answer": "Output: WT1 mutations can cause the following diseases: Frasier syndrome, Wilms' tumor-Aniridia-ambiguous Genitals-mental Retardation, and mesothelioma."
    },
    {
        "question": "What diseases can be caused by mutations in the CHEK2 gene?",
        "answer": "Output: CHEK2 mutations can cause osteosarcoma and other bone tumors."
    },
    {
        "question": "What diseases can NF2 gene mutation lead to?",
        "answer": "Output: NF2 gene mutation can lead to neurofibromatosis type 2."
    },
    {
        "question": "What diseases can DICER1 lead to?",
        "answer": "Output: DICER1 can lead to the following diseases: renal cell carcinoma."
    },
    {
        "question": "What diseases can ELANE gene mutation lead to?",
        "answer": "Output: ELANE gene mutation can lead to the following diseases: Kostmann syndrome, acute myeloid leukemia, and multiple myeloma."
    },
    {
        "question": "What is the relationship between LIG4 and prostate?",
        "answer": "Output: LIG4 is a transcription factor that regulates the expression of genes involved in cell growth and differentiation."
    },
    {
        "question": "What is the relationship between breast and CDH1?",
        "answer": "Output: Breast is a type of cancer that is driven by CDH1."
    },
    {
        "question": "What is the relationship between medulloblastoma and HRAS?",
        "answer": "Output: Medulloblastoma is related to HRAS through the following pathways: HRAS is activated by FGFR1 in medulloblastoma."
    },
    {
        "question": "What is the relationship between CEBPA and RUNX1T1?",
        "answer": "Output: CEBPA inhibits RUNX1T1."
    },
    {
        "question": "What is the relationship between PRDM2 and anal carcinoma?",
        "answer": "Output: PRDM2 is a gene that is associated with anal carcinoma."
    },
    {
        "question": "What is the relationship between breast and SMARCA4?",
        "answer": "Output: There is no relationship between breast and SMARCA4."
    },
    {
        "question": "What is the relationship between esophageal carcinoma and RARA?",
        "answer": "Output: There is no known relationship between esophageal carcinoma and RARA."
    },
    {
        "question": "What is the relationship between anal carcinoma and TP53?",
        "answer": "Output: Anal carcinoma is a type of TP53."
    },
    {
        "question": "What is the relationship between DAXX and TGFBR2?",
        "answer": "Output: DAXX is a downstream target of TGFBR2."
    },
    {
        "question": "What is the relationship between APC and TCF7L2?",
        "answer": "Output: APC is a downstream target of TCF7L2."
    },
    {
        "question": "What is the relationship between NCOR1 and FBXW7?",
        "answer": "Output: NCOR1 and FBXW7 are mutually exclusive."
    },
    {
        "question": "What is the relationship between SMO and SHH?",
        "answer": "Output: SMO inhibits SHH."
    },
    {
        "question": "What is the relationship between PML and SPI1?",
        "answer": "Output: PML is a tumor suppressor gene that is inhibited by SPI1."
    },
    {
        "question": "What is the relationship between MAX and MDM2?",
        "answer": "Output: MAX is a transcription factor that regulates MDM2."
    },
    {
        "question": "What is the relationship between MYC and GSK3B?",
        "answer": "Output: GSK3B regulates MYC."
    },
    {
        "question": "What diseases can TBXT lead to?",
        "answer": "Output: TBXT can lead to the following diseases: renal cell carcinoma, lung cancer, and breast cancer."
    },
    {
        "question": "What is the relationship between WHIM syndrome and CXCR4?",
        "answer": "Output: WHIM syndrome is caused by CXCR4."
    },
    {
        "question": "What is the relationship between kaposis sarcoma and IL6?",
        "answer": "Output: IL6 is a tumor-promoting cytokine that is involved in the development of Kaposi's sarcoma."
    },
    {
        "question": "What is the relationship between ovarian carcinoma and WT1?",
        "answer": "Output: Ovarian carcinoma is caused by WT1."
    },
    {
        "question": "What is the relationship between pheochromocytoma and TMEM127?",
        "answer": "Output: pheochromocytoma is a rare tumor that is caused by mutations in the TMEM127 gene."
    },
    {
        "question": "What is the relationship between Cowden syndrome 1 and uterus?",
        "answer": "Output: Cowden syndrome 1 is a congenital disorder of the uterus."
    },
    {
        "question": "What is the relationship between Inherited Epidermolysis Bullosa and MMP1?",
        "answer": "Output: Inherited Epidermolysis Bullosa is caused by MMP1."
    },
    {
        "question": "Which type of cancer is likely to be driven by ENPEP?",
        "answer": "Output: ENPEP is likely to drive colon cancer."
    },
    {
        "question": "Which type of cancer is likely to be driven by PRDM2?",
        "answer": "Output: PRDM2 is likely to drive the following types of cancer: renal cell carcinoma, urothelial carcinoma, and hepatocellular carcinoma."
    },
    {
        "question": "Which type of cancer is likely to be driven by GTF2I?",
        "answer": "Output: GTF2I is likely to drive renal cell carcinoma."
    },
    {
        "question": "How would you describe docetaxel?",
        "answer": "Output: Docetaxel is a taxane drug that is used to treat various types of cancer, including breast cancer, ovarian cancer, and prostate cancer. It works by inhibiting the growth of new blood vessels that feed tumors, which can slow the growth of tumors and delay the progression of cancer."
    },
    {
        "question": "How would you describe fulvestrant?",
        "answer": "Output: Fulvestrant is a drug that can suppress the growth of breast cancer cells and is used to treat breast cancer."
    },
    {
        "question": "How would you describe Bloom syndrome?",
        "answer": "Output: Bloom syndrome is a rare genetic disorder that causes a range of symptoms, including skin sensitivity to light, red spots on the face and hands, and a low birth weight. It is caused by a mutation in the BLM gene."
    },
    {
        "question": "How would you describe Frasier syndrome?",
        "answer": "Output: Frasier syndrome is a rare genetic disorder that affects the kidney and reproductive system. It is characterized by a combination of kidney disease and reproductive system abnormalities."
    },
    {
        "question": "How would you describe Mulibrey Nanism?",
        "answer": "Output: Mulibrey nanism is a rare genetic disorder that affects the development of the face and body, including a triangular face shape, high-pitched voice, and a yellowish discoloration of the eyes."
    },
    {
        "question": "How would you describe Weaver syndrome?",
        "answer": "Output: Weaver syndrome is a rare genetic disorder that affects the growth and development of bones, joints, and facial features. It is characterized by rapid growth and development, clubfoot, and facial abnormalities. It is also associated with other health problems, such as joint contractures and difficulty walking or running."
    },
    {
        "question": "How to treat giant cell carcinoma of the lung with POLE?",
        "answer": "Output: POLE can be used to treat giant cell carcinoma of the lung."
    },
    {
        "question": "How to treat soft tissue with KIT?",
        "answer": "Output: KIT can be treated with the following drugs: imatinib, nilotinib, and dasatinib."
    },
    {
        "question": "How to treat soft tissue with PDGFRA?",
        "answer": "Output: Soft tissue can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat myeloid with KIT?",
        "answer": "Output: Myeloid with KIT can be treated with the following drugs: imatinib, nilotinib, and dasatinib."
    },
    {
        "question": "How to treat unclassified renal cell carcinoma with VHL?",
        "answer": "Output: Unclassified renal cell carcinoma with VHL can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat cholangiocarcinoma with FGFR2?",
        "answer": "Output: Cholangiocarcinoma with FGFR2 can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat ovarian seromucinous carcinoma with PIK3CA?",
        "answer": "Output: Ovarian seromucinous carcinoma with PIK3CA can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat uterine dedifferentiated carcinoma with AKT1?",
        "answer": "Output: Uterine dedifferentiated carcinoma with AKT1 can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "How to treat colorectal adenocarcinoma with KRAS?",
        "answer": "Output: Colorectal adenocarcinoma with KRAS can be treated with the following drugs: cabozantinib, voronib, lenvatinib, nivolumab, pembrolizumab, ipilimumab, acitinib, tivozanib, temsirolimus, and tigafur."
    },
    {
        "question": "What type of cancer can TCF7L2 drive?",
        "answer": "Output: TCF7L2 can drive breast cancer."
    },
    {
        "question": "What type of cancer can SMAD2 drive?",
        "answer": "Output: SMAD2 can drive breast cancer, lung cancer, and renal cell carcinoma."
    },
    {
        "question": "What type of cancer can NIN drive?",
        "answer": "Output: NIN can drive the following types of cancer: renal cell carcinoma."
    },
    {
        "question": "What type of cancer can FBXW7 drive?",
        "answer": "Output: FBXW7 can drive the following types of cancer: gastric cancer, stomach cancer, pancreatic cancer, kidney cancer, liver cancer, breast cancer, lung cancer, head and neck cancer, and nasopharyngeal cancer."
    },
    {
        "question": "What type of cancer can ARID1A drive?",
        "answer": "Output: ARID1A can drive the following types of cancer: renal cell carcinoma, pancreatic adenocarcinoma, and gastric adenocarcinoma."
    },
    {
        "question": "What type of cancer can POLD1 drive?",
        "answer": "Output: POLD1 can drive breast cancer."
    },
    {
        "question": "What type of cancer can Androgen Insensitivity Syndrome develop?",
        "answer": "Output: Androgen Insensitivity Syndrome can develop breast cancer."
    },
    {
        "question": "What type of cancer can WHIM syndrome develop?",
        "answer": "Output: WHIM syndrome can develop various types of cancer, including breast cancer, ovarian cancer, uterine cancer, cervical cancer, and renal cell cancer."
    },
    {
        "question": "What type of cancer can Porokeratosis develop?",
        "answer": "Output: Porokeratosis can develop into renal cell carcinoma."
    },
    {
        "question": "What type of cancer can Familial Paragangliomas develop?",
        "answer": "Output: Familial Paragangliomas can develop renal cell carcinoma."
    },
    {
        "question": "What type of cancer can Juvenile Polyposis develop?",
        "answer": "Output: Juvenile polyposis can develop renal cell carcinoma."
    },
    {
        "question": "Is carteolol effective in treating hemangioma?",
        "answer": "Output: Yes, carteolol is effective in treating hemangioma."
    },
    {
        "question": "Is FCN-159 effective in treating melanoma?",
        "answer": "Output: Yes, FCN-159 is effective in treating melanoma."
    }
]